Live
- Damson Technologies Inaugurates State-of-the-Art Manufacturing Facility in Ahmedabad with Rs. 200 Crore planned Investment
- Waqf row: BJP stages protest condemning land grab in Karnataka
- President Droupadi Murmu Graces Koti Deepotsavam in Hyderabad
- South Korean court sentences ex-fiance of Olympic fencing medalist to 13-yr prison term
- Posani Krishna Murali Announces Exit from Politics
- Allu Arjun and Sreeleela to Ignite the Stage with Pushpa-2’s Special Song
- World Television Day 2024: From B&W Beginnings to Smart TVs and Their Role in Shaping Elections
- Bihar: Kaimur residents buy cheap medicines from Jan Aushadhi Kendras, thanks govt
- JMM confident of winning 59 seats in Jharkhand
- Jordan's govt approves draft budget law for 2025
Glenmark Pharmarolls outlow-cost drug for diabetes
Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
Hyderabad: Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
The drug was launched under brand names Remo and Remozen, at a price of Rs 12.50 per tablet.
The new diabetic drug, Remogliflozin, was discovered and developed by Japanese firm Kissei Pharmaceutical Co Ltd and later developed by GlaxoSmithKline plc and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, Inc.
The drug company expects 12 to 14 per cent growth in its India revenues during the current fiscal, Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals said.
